Production (Stage)
BetterLife Pharma Inc.
BETR
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.88M | 3.14M | 3.12M | 3.02M | 3.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.11M | 3.45M | 3.55M | 3.54M | 3.49M |
| Operating Income | -2.11M | -3.45M | -3.55M | -3.54M | -3.49M |
| Income Before Tax | -1.27M | -2.64M | -2.61M | -3.24M | -2.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.27 | -2.64 | -2.61 | -3.24 | -2.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.70K | 73.90K | -399.30K | -355.70K | -355.90K |
| Net Income | -1.28M | -2.56M | -3.01M | -3.59M | -3.31M |
| EBIT | -2.11M | -3.45M | -3.55M | -3.54M | -3.49M |
| EBITDA | -- | -- | -537.50K | -1.05M | -1.81M |
| EPS Basic | -0.01 | -0.02 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 509.56M | 495.35M | 480.72M | 464.10M | 452.84M |
| Average Diluted Shares Outstanding | 526.86M | 512.64M | 498.01M | 464.10M | 452.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |